MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Infectious Disease_Hepatitis
Regulus Therapeutics Inc. (NASDAQ: RGLS)*
Finance & Acquisitions: Regulus
Parents
Regulus Therapeutics Inc. (NASDAQ: RGLS)*
Children
*Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development of microRNA
2010: Sanofi-Aventis Completes $10 Million Equity Investment in Regulus Therapeutics (2010)
2012: Regulus Therapeutics Files for IPO as ‘Emerging Growth’ Company (2012)
2025: Novartis to buy kidney-focused Regulus for $800 million upfront
2025: Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
50/50 joint venture between Cambridge, MA-based Alnylam Pharmaceuticals (NADSAQ: ALNY), an RNA-interference drug developer, and Carlsbad, CA-based Isis Pharmaceuticals (NADSAQ: ISIS), a pioneer in antisense drug technology
Regulus Therapeutics Inc Stock Quote: RGLS Stock News, Quotes, Analysis
Regulus_Analysts nasdaq
Jumps
*Key People: Regulus
Organization & Developments: Regulus